Topic: monoclonal antibody
HiFiBiO Therapeutics has had a busy year, as pacts and raises abound, and it’s showing no signs of slowing down as it gets its checkbook out for an unusual French spinout.
A phase 2 study of Xencor’s lead antibody missed its primary endpoint in lupus, though the company described the data as worthy of future study.
Celgene is walking away from navicixizumab, a bispecific antibody that became OncoMed’s lead asset after midstage failures scuppered a couple of other candidates.
The series C round comes as Atreca gears up to move its lead solid tumor drug into the clinic and boost the throughput of its discovery engine.
Pfizer halted two phase 2 trials of its Duchenne muscular dystrophy drug domagrozumab after the main efficacy study failed its primary endpoint.
Y-mAbs Therapeutics filed to raise up to $92 million in its IPO to advance a pair of pivotal-stage meds for childhood brain cancers.
A discontinued heart disease drug will be developed for sickle cell, with Roche handing off its inclacumab antibody to Global Blood Therapeutics.
Aridis filed for a $34.5 million IPO as it plans to move its fully human antibodies for hospital-related infections into late-phase clinical trials.
Compass Therapeutics is coming out of stealth with $132 million in series A cash, 15 prospects in preclinical development and a lead oncology asset poised to enter the clinic in 2019.
Otsuka plans to acquire Visterra and its antibody engineering platform for $430 million in cash, as it aims to build out its discovery efforts.